ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2038

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis

C. April Bingham1, Jesse Pratt2, Cagri Yildirim-Toruner3, Ronald Laxer4, Beth Gottlieb5, Jennifer E. Weiss6, Tzielan Lee7, Sheetal S. Vora8, Jon M. Burnham9, Julia Harris10, Judyann C. Olson11, Murray Passo12, Michelle Batthish13, Michael Shishov14, Kerry Ferraro15, Deborah M. Levy16, Christine O'Brien17, Kristi Whitney-Mahoney17, Nancy Griffin18, Anne Paul19 and Esi Morgan20, 1Penn State Health Children's Hospital, Hershey, PA, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Rheumatology, Nationwide Children's Hospital, Columbus, OH, 4Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 5Pediatrics, Cohen Children's Medical Center, Lake Success, NY, 6Hackensack Univ Med Ctr, Hackensack, NJ, 7Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 8Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 9Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, 10Children's Mercy Kansas City, Kansas City, MO, 11Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, 12Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 13Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, 14Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, 15Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 16Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 17The Hospital for Sick Children, Toronto, ON, Canada, 18James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 19Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 20Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: juvenile idiopathic arthritis (JIA), Outcome measures, Pediatric rheumatology, quality improvement and quality measures

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Quality Measures and Quality of Care I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes of care for children with juvenile idiopathic arthritis (JIA). Since 2011, data from JIA clinical encounters have been entered into a shared registry to track performance on process and outcome quality measures (QMs) to drive improved outcomes. Currently, 17 centers learn established quality improvement methodology to conduct quality improvement work and share best practices at biannual face-to-face learning sessions and monthly webinars.

Methods: Statistical process control methods are used to determine if there are changes in performance on the QMs. A centerline (the mean of the first 12 months of data) and control limits (±3 SD) are calculated, and control charts are monitored for special causes. Site specific and aggregate control charts are displayed monthly. If it is determined that a sustainable change has occurred, a new centerline and new control limits are calculated. Process QMs include measurement of: arthritis-related pain, physician global assessment of disease activity (PGA), joint counts, health related quality of life, physical function, medication counseling, as well as adherence to guidelines for uveitis screening, medication toxicity monitoring, and tuberculosis screening. Outcome QMs include: proportion of patients with clinical inactive disease (CID), mild to no pain, and optimal physical function; mean clinical Juvenile Arthritis Disease Activity Score 10 (cJADAS10); and percent of polyarthritis or oligoarthritis patients with inactive or low disease activity by cJADAS10.

Results: As of May 2016, 3716 JIA patients are enrolled, with over 20,000 visits recorded in the registry. Performance improvements have been achieved in process QMs, including percent of patients on Disease Modifying Anti Rheumatic Drug (DMARD) who had appropriate toxicity lab monitoring (from 56 to 82%) and documented medication counseling with DMARD initiation (from 59 to 93%). In addition, PR-COIN sites reliably perform complete joint counts (99%), PGA (96%), measurement of arthritis-related pain (94%), and tuberculosis screening for patients newly prescribed biologic drugs (99%). Forty-two percent of all PR-COIN patients have CID, with marked center-to-center variability (range 25% to 59%) and statistical improvement in a subset of centers. Seventy-five percent of patients have mild to no pain, and 60% have optimal physical function. PR-COIN has shown improved outcomes in mean cJADAS10 scores (from 4.4 to 3.8) and percentage of patients with inactive or low disease activity by cJADAS10 (from 49 to 54%) from 2011 to present.

Conclusion: PR-COIN has demonstrated success in improving processes of care for management of JIA. There is, however, variability in performance across centers. The dichotomous outcome measure “clinical inactive disease” has been slow to show statistical improvement in aggregate. By adopting a continuous outcome measure, the cJADAS10, PR-COIN has been able to demonstrate incremental improvements in outcomes for patients with JIA.


Disclosure: C. A. Bingham, None; J. Pratt, None; C. Yildirim-Toruner, None; R. Laxer, Novartis Pharmaceutical Corporation; Abbvie; Sanofi, 5; B. Gottlieb, None; J. E. Weiss, None; T. Lee, None; S. S. Vora, None; J. M. Burnham, None; J. Harris, None; J. C. Olson, None; M. Passo, Pfizer Pharmaceuticals, 5; M. Batthish, Abbvie, 9; M. Shishov, Novartis Pharmaceutical Corporation, 5; K. Ferraro, None; D. M. Levy, None; C. O'Brien, None; K. Whitney-Mahoney, None; N. Griffin, None; A. Paul, None; E. Morgan, None.

To cite this abstract in AMA style:

Bingham CA, Pratt J, Yildirim-Toruner C, Laxer R, Gottlieb B, Weiss JE, Lee T, Vora SS, Burnham JM, Harris J, Olson JC, Passo M, Batthish M, Shishov M, Ferraro K, Levy DM, O'Brien C, Whitney-Mahoney K, Griffin N, Paul A, Morgan E. Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pediatric-rheumatology-care-and-outcomes-improvement-network-demonstrates-improvement-on-quality-measures-for-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-rheumatology-care-and-outcomes-improvement-network-demonstrates-improvement-on-quality-measures-for-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology